Masaaki Yanishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masaaki Yanishi has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Hidefumi Kinoshita
Department of Urology and Andrology, Kansai Medical University, Osaka, Japan
13 shared publicationsKenji Yoshida
Department of Urology and Andrology, Kansai Medical University, Osaka, Japan
8 shared publicationsMotohiko Sugi
Department of Urology and Andrology, Kansai Medical University, Osaka, Japan
8 shared publicationsTadashi Matsuda
Department of Urology and Andrology, Kansai Medical University, Osaka, Japan
8 shared publicationsYuya Koito
Department of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan
8 shared publicationsHisanori Taniguchi
Department of Urology and Andrology, Kansai Medical University, Osaka, Japan
7 shared publications
Latest Publications
- 27 May 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (6) , 3453-3459
Three-factor Clinical Score for First-line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma
Nivolumab plus ipilimumab (NIVO-IPI) provides durable disease control in a subset of patients with metastatic renal cell carcinoma (mRCC). However, reliable clinical tools for identifying this patient population remain undefined. We aimed to develop a simple clinical score to stratify outcomes in real-world patients treated with first-line NIVO-IPI. We conducted a multicenter retrospective analysis of 65 consecutive patients with untreated mRCC who received first-line NIVO-IPI. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox proportional hazards model. Based on Cox regression findings and clinical interpretability, a three-factor clinical score was constructed assigning one point each for International Metastatic RCC Database Consortium (IMDC) poor risk (score ≥3), presence of bone metastasis, and elevated baseline C-reactive protein (CRP ≥1 mg/dl). Patients were stratified into three groups (scores 0, 1, and ≥2). Among the 65 patients included, the median PFS and OS were 10.1 and 35.3 months, respectively, and the 12-month PFS and OS rates were 41.9% and 75.5%, respectively. The three-factor score effectively stratified the outcomes. Median PFS was not reached, not reached, and 5.9 months in patients with scores 0, 1, and ≥2, respectively, with corresponding 12-month PFS rates of 72.9, 58.0, and 14.4%. Median OS was not reached, 36.5 months, and 16.8 months, with corresponding 12-month OS rates of 94.4, 92.9, and 54.7%. The developed three-factor clinical score incorporating IMDC risk, bone metastasis, and baseline CRP effectively stratified real-world patients treated with first-line NIVO-IPI. Patients without these risk factors achieved sustained disease control, whereas those with ≥2 risk factors had significantly inferior outcomes. This tool may assist in selecting patients most likely to derive durable benefits from NIVO-IPI in routine clinical practice.
- 27 May 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (6) , 3453-3459
Three-factor Clinical Score for First-line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma
Nivolumab plus ipilimumab (NIVO-IPI) provides durable disease control in a subset of patients with metastatic renal cell carcinoma (mRCC). However, reliable clinical tools for identifying this patient population remain undefined. We aimed to develop a simple clinical score to stratify outcomes in real-world patients treated with first-line NIVO-IPI. We conducted a multicenter retrospective analysis of 65 consecutive patients with untreated mRCC who received first-line NIVO-IPI. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox proportional hazards model. Based on Cox regression findings and clinical interpretability, a three-factor clinical score was constructed assigning one point each for International Metastatic RCC Database Consortium (IMDC) poor risk (score ≥3), presence of bone metastasis, and elevated baseline C-reactive protein (CRP ≥1 mg/dl). Patients were stratified into three groups (scores 0, 1, and ≥2). Among the 65 patients included, the median PFS and OS were 10.1 and 35.3 months, respectively, and the 12-month PFS and OS rates were 41.9% and 75.5%, respectively. The three-factor score effectively stratified the outcomes. Median PFS was not reached, not reached, and 5.9 months in patients with scores 0, 1, and ≥2, respectively, with corresponding 12-month PFS rates of 72.9, 58.0, and 14.4%. Median OS was not reached, 36.5 months, and 16.8 months, with corresponding 12-month OS rates of 94.4, 92.9, and 54.7%. The developed three-factor clinical score incorporating IMDC risk, bone metastasis, and baseline CRP effectively stratified real-world patients treated with first-line NIVO-IPI. Patients without these risk factors achieved sustained disease control, whereas those with ≥2 risk factors had significantly inferior outcomes. This tool may assist in selecting patients most likely to derive durable benefits from NIVO-IPI in routine clinical practice.
- 27 March 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (4) , 2145-2151
Real-world Comparative Study of Androgen Receptor Signaling Inhibitors in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer
Androgen receptor signaling inhibitors (ARSIs) are widely used for non-metastatic castration-resistant prostate cancer (nmCRPC). However, real-world data comparing clinical outcomes and treatment persistence among ARSIs in Asian populations remain limited. This study aimed to evaluate real-world effectiveness and tolerability of ARSIs in Japanese patients with nmCRPC. We retrospectively reviewed 100 Japanese patients with nmCRPC treated with enzalutamide (ENZ), apalutamide (APA), or darolutamide (DARO) at Kansai Medical University and its affiliated hospitals between May 2020 and December 2024. Progression-free survival (PFS), overall survival (OS), prostate-specific antigen (PSA) response, treatment sequencing, and adverse event-related dose modification or discontinuation were analyzed using Kaplan-Meier and log-rank tests. The median PFS for the entire cohort was 21.5 months. ENZ showed significantly longer PFS compared with APA (p=0.03), while DARO demonstrated comparable outcomes to both agents. OS did not differ significantly among groups. Patients receiving ARSI as first-line therapy had significantly longer PFS than those treated with second-line ARSIs. Initiation of ARSI therapy at PSA levels <2.0 ng/ml was associated with improved PFS. Second-line ARSI therapy showed limited PSA response and shorter PFS. Adverse event-related dose reduction or treatment discontinuation was associated with poorer PFS, with dermatologic toxicity being the main cause of APA discontinuation. In Japanese real-world practice, ARSI effectiveness in nmCRPC appears influenced by treatment persistence, timing of initiation, and treatment sequencing. Early initiation and careful management of adverse events may optimize outcomes, whereas sequential ARSI use shows limited benefit.
- 27 March 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (4) , 2145-2151
Real-world Comparative Study of Androgen Receptor Signaling Inhibitors in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer
Androgen receptor signaling inhibitors (ARSIs) are widely used for non-metastatic castration-resistant prostate cancer (nmCRPC). However, real-world data comparing clinical outcomes and treatment persistence among ARSIs in Asian populations remain limited. This study aimed to evaluate real-world effectiveness and tolerability of ARSIs in Japanese patients with nmCRPC. We retrospectively reviewed 100 Japanese patients with nmCRPC treated with enzalutamide (ENZ), apalutamide (APA), or darolutamide (DARO) at Kansai Medical University and its affiliated hospitals between May 2020 and December 2024. Progression-free survival (PFS), overall survival (OS), prostate-specific antigen (PSA) response, treatment sequencing, and adverse event-related dose modification or discontinuation were analyzed using Kaplan-Meier and log-rank tests. The median PFS for the entire cohort was 21.5 months. ENZ showed significantly longer PFS compared with APA (p=0.03), while DARO demonstrated comparable outcomes to both agents. OS did not differ significantly among groups. Patients receiving ARSI as first-line therapy had significantly longer PFS than those treated with second-line ARSIs. Initiation of ARSI therapy at PSA levels <2.0 ng/ml was associated with improved PFS. Second-line ARSI therapy showed limited PSA response and shorter PFS. Adverse event-related dose reduction or treatment discontinuation was associated with poorer PFS, with dermatologic toxicity being the main cause of APA discontinuation. In Japanese real-world practice, ARSI effectiveness in nmCRPC appears influenced by treatment persistence, timing of initiation, and treatment sequencing. Early initiation and careful management of adverse events may optimize outcomes, whereas sequential ARSI use shows limited benefit.
- 9 January 2026
- Published by Elsevier in Transplantation Proceedings
- Vol. 58 (1) , 52-57
Low Preoperative Exercise Tolerance Predicts Impaired Skeletal Muscle Recovery After Kidney Transplantation
- 9 January 2026
- Published by Elsevier in Transplantation Proceedings
- Vol. 58 (1) , 52-57
Low Preoperative Exercise Tolerance Predicts Impaired Skeletal Muscle Recovery After Kidney Transplantation
- 29 November 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (12) , e70405
Effects of Perioperative Rehabilitation on Physical Function in Kidney Transplant Recipients
Background: Sarcopenia and frailty are common among kidney transplant candidates and often persist even after transplantation. Exercise therapy initiated during the perioperative period may improve physical function, but its benefits remain underexplored. Methods: We conducted a single‐center prospective observational study evaluating a structured rehabilitation protocol in kidney transplant recipients. Patients received supervised exercise therapy starting from postoperative day (POD) 2, followed by resistance training and aerobic exercise during hospitalization. Upon discharge, participants were instructed to continue monthly supervised training sessions. Outcomes including skeletal muscle index (SMI), handgrip strength, gait speed, anaerobic threshold VO 2 , and peak VO 2 were assessed before transplant and at 1 year post‐transplant. Improvement rates were compared between patients who received rehabilitation and those who did not, and further among those who continued post‐discharge training. Results: Patients in the rehabilitation group showed significantly greater improvements in grip strength, gait speed, and VO 2 parameters compared to the control group ( p < 0.05). Among the rehabilitation group, those who continued training post‐discharge for ≥6 months exhibited the most pronounced improvements. No adverse effects on renal function were observed. Conclusions: Early and sustained rehabilitation is effective and safe for improving physical function in kidney transplant recipients. Incorporating structured exercise therapy into routine perioperative and post‐discharge care may enhance recovery and clinical outcomes.
- 29 November 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (12) , e70405
Effects of Perioperative Rehabilitation on Physical Function in Kidney Transplant Recipients
Background: Sarcopenia and frailty are common among kidney transplant candidates and often persist even after transplantation. Exercise therapy initiated during the perioperative period may improve physical function, but its benefits remain underexplored. Methods: We conducted a single‐center prospective observational study evaluating a structured rehabilitation protocol in kidney transplant recipients. Patients received supervised exercise therapy starting from postoperative day (POD) 2, followed by resistance training and aerobic exercise during hospitalization. Upon discharge, participants were instructed to continue monthly supervised training sessions. Outcomes including skeletal muscle index (SMI), handgrip strength, gait speed, anaerobic threshold VO 2 , and peak VO 2 were assessed before transplant and at 1 year post‐transplant. Improvement rates were compared between patients who received rehabilitation and those who did not, and further among those who continued post‐discharge training. Results: Patients in the rehabilitation group showed significantly greater improvements in grip strength, gait speed, and VO 2 parameters compared to the control group ( p < 0.05). Among the rehabilitation group, those who continued training post‐discharge for ≥6 months exhibited the most pronounced improvements. No adverse effects on renal function were observed. Conclusions: Early and sustained rehabilitation is effective and safe for improving physical function in kidney transplant recipients. Incorporating structured exercise therapy into routine perioperative and post‐discharge care may enhance recovery and clinical outcomes.
- 29 July 2024
- Published by Wiley in International Journal of Urology
- Vol. 31 (10) , 1108-1113
Trifecta outcomes of robotic partial nephrectomy in obese patients: A comparison of body mass index <25, 25 to <30, and ≥30
Objective: We analyzed robotic partial nephrectomy (RPN) outcomes in obese patients based on body mass index (BMI) and trifecta achievement.Methods: We retrospectively reviewed 296 patients who underwent RPN at Kansai Medical University Hospital between 2014 and 2022. The preoperative clinical data and perioperative outcomes were evaluated. Trifecta achievement (negative surgical margin, no major complications, and no acute kidney injury on postoperative day three) and its relationship to three BMI groups (p = 0.566). Intraoperative blood loss increased with the BMI (p = 0.034). Multivariate analyses showed preoperative aspects and dimensions used for anatomic (PADUA) score independently predicted trifecta failure (odds ratio 1.71; 95% confidence interval 1.32–2.20;p < 0.001). The C‐statistics of the PADUA score increased with increasing BMI.Conclusions: Higher BMI patients had more intraoperative blood loss during RPN. However, RPN remains safe and has acceptable quality and functional outcomes. Since patients with high PADUA scores combined with a high BMI may be at risk of trifecta failure, this should be explained before RPN.
- 29 July 2024
- Published by Wiley in International Journal of Urology
- Vol. 31 (10) , 1108-1113
Trifecta outcomes of robotic partial nephrectomy in obese patients: A comparison of body mass index <25, 25 to <30, and ≥30
Objective: We analyzed robotic partial nephrectomy (RPN) outcomes in obese patients based on body mass index (BMI) and trifecta achievement.Methods: We retrospectively reviewed 296 patients who underwent RPN at Kansai Medical University Hospital between 2014 and 2022. The preoperative clinical data and perioperative outcomes were evaluated. Trifecta achievement (negative surgical margin, no major complications, and no acute kidney injury on postoperative day three) and its relationship to three BMI groups (p = 0.566). Intraoperative blood loss increased with the BMI (p = 0.034). Multivariate analyses showed preoperative aspects and dimensions used for anatomic (PADUA) score independently predicted trifecta failure (odds ratio 1.71; 95% confidence interval 1.32–2.20;p < 0.001). The C‐statistics of the PADUA score increased with increasing BMI.Conclusions: Higher BMI patients had more intraoperative blood loss during RPN. However, RPN remains safe and has acceptable quality and functional outcomes. Since patients with high PADUA scores combined with a high BMI may be at risk of trifecta failure, this should be explained before RPN.
- Open Access
- 31 March 2022
- Published by Springer Nature in BMC Nephrology
- Vol. 23 (1) , 1-6
Urinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury
Background: Although cisplatin-based chemotherapy is a standard treatment for urothelial carcinoma, it often causes acute kidney injury (AKI). AKI and dysfunction are observed in 25–35% of cisplatin-based chemotherapy patients, who may require treatment down-titration or withdrawal. In this study, we evaluated whether urinary L-FABP is a marker for early diagnosis of cisplatin-caused AKI. Methods: We included 42 adult patients who underwent cisplatin-based chemotherapy for bladder cancer or upper tract urothelial carcinoma from January 2018 to March 2019. Urinary L-FABP and serum creatinine were measured at 2 and 6 h, and 1, 2, 3, 7 and 28 days after taking cisplatin. Results: In the first week after receiving cisplatin, 10 patients (23.8%) were diagnosed with AKI (AKI+ group). Pre-treatment (baseline) measurements did not significantly differ between the AKI+ and AKI− groups. However, urinary L-FABP concentrations rapidly increased in the AKI+ group and were significantly greater than in the AKI− group at Hour 2, Hour 6, Day 1 and Day 2. Serum creatinine also significantly differed between the AKI+ group and the AKI− group on Days 3 and 7. ROC analysis was performed to evaluate the superiority of urinary L-FABP magnification which had the highest at the hour 6. The urinary L-FABP magnification and levels of aria under curve was 0.977. Based on ROC analysis, the best cut-off value of urinary L-FABP magnification was 10.28 times urinary L-FABP levels at the hour 0 (base line urinary L-FABP). Conclusions: Acute renal function deterioration was predicted by increased urinary L-FABP excretion within 6 h after receiving CIS-CT and, in those with AKI, the increase in urinary L-FABP excretion preceded the rise in sCr by over 2 days. In contrast, no appreciable changes in urinary L-FABP levels were observed in patients with stable renal function throughout the whole observation period. So early increase in urinary L-FABP may identify patients at risk of cisplatin-induced AKI, who might benefit from treatment to prevent nephrotoxicity. Trial registration: This study was retrospectively registered.
- 31 March 2022
- Published by Springer Nature in BMC Nephrology
- Vol. 23 (1) , 1-6
Open AccessUrinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury
Background: Although cisplatin-based chemotherapy is a standard treatment for urothelial carcinoma, it often causes acute kidney injury (AKI). AKI and dysfunction are observed in 25–35% of cisplatin-based chemotherapy patients, who may require treatment down-titration or withdrawal. In this study, we evaluated whether urinary L-FABP is a marker for early diagnosis of cisplatin-caused AKI. Methods: We included 42 adult patients who underwent cisplatin-based chemotherapy for bladder cancer or upper tract urothelial carcinoma from January 2018 to March 2019. Urinary L-FABP and serum creatinine were measured at 2 and 6 h, and 1, 2, 3, 7 and 28 days after taking cisplatin. Results: In the first week after receiving cisplatin, 10 patients (23.8%) were diagnosed with AKI (AKI+ group). Pre-treatment (baseline) measurements did not significantly differ between the AKI+ and AKI− groups. However, urinary L-FABP concentrations rapidly increased in the AKI+ group and were significantly greater than in the AKI− group at Hour 2, Hour 6, Day 1 and Day 2. Serum creatinine also significantly differed between the AKI+ group and the AKI− group on Days 3 and 7. ROC analysis was performed to evaluate the superiority of urinary L-FABP magnification which had the highest at the hour 6. The urinary L-FABP magnification and levels of aria under curve was 0.977. Based on ROC analysis, the best cut-off value of urinary L-FABP magnification was 10.28 times urinary L-FABP levels at the hour 0 (base line urinary L-FABP). Conclusions: Acute renal function deterioration was predicted by increased urinary L-FABP excretion within 6 h after receiving CIS-CT and, in those with AKI, the increase in urinary L-FABP excretion preceded the rise in sCr by over 2 days. In contrast, no appreciable changes in urinary L-FABP levels were observed in patients with stable renal function throughout the whole observation period. So early increase in urinary L-FABP may identify patients at risk of cisplatin-induced AKI, who might benefit from treatment to prevent nephrotoxicity. Trial registration: This study was retrospectively registered.
- Open Access
- 14 October 2021
- Published by Springer Nature in Research Square
Urinary L-Type Fatty Acid-Binding Protein is a Predictor of Cisplatin-Induced Acute Kidney Injury.
Background Although cisplatin-based chemotherapy is a standard treatment for urothelial carcinoma, it often causes acute kidney injury (AKI). AKI and dysfunction are observed in 25–35% of cisplatin-based chemotherapy patients, who may require treatment down-titration or withdrawal. In this study, we evaluated whether urinary L-FABP is a marker for early diagnosis of cisplatin-caused AKI. Methods We included 42 adult patients who underwent cisplatin-based chemotherapy for bladder cancer or upper tract urothelial carcinoma from January 2018 to March 2019. Urinary L-FABP and serum creatinine were measured at 2 and 6 hours, and 1, 2, 3, 7 and 28 days after taking cisplatin. Results In the first week after receiving cisplatin, 10 patients (23.8%) were diagnosed with AKI (AKI+ group). Pre-treatment (baseline) measurements did not significantly differ between the AKI+ and AKI− groups. However, urinary L-FABP concentrations rapidly increased in the AKI+ group and were significantly greater than in the AKI− group at Hour 2, Hour 6, Day 1 and Day 2. Serum creatinine also significantly differed between the AKI+ group and the AKI− group on Days 3 and 7. Conclusions Acute renal function deterioration was predicted by increased urinary L-FABP excretion within six hours after receiving CIS-CT and, in those with AKI, the increase in urinary L-FABP excretion preceded the rise in sCr by over 2 days. In contrast, no appreciable changes in urinary L-FABP levels were observed in patients with stable renal function throughout the whole observation period. So early increase in urinary L-FABP may identify patients at risk of cisplatin-induced AKI, who might benefit from treatment to prevent nephrotoxicity. Trial registration: This study was retrospectively registered.
- 14 October 2021
- Published by Springer Nature in Research Square
Open AccessUrinary L-Type Fatty Acid-Binding Protein is a Predictor of Cisplatin-Induced Acute Kidney Injury.
Background Although cisplatin-based chemotherapy is a standard treatment for urothelial carcinoma, it often causes acute kidney injury (AKI). AKI and dysfunction are observed in 25–35% of cisplatin-based chemotherapy patients, who may require treatment down-titration or withdrawal. In this study, we evaluated whether urinary L-FABP is a marker for early diagnosis of cisplatin-caused AKI. Methods We included 42 adult patients who underwent cisplatin-based chemotherapy for bladder cancer or upper tract urothelial carcinoma from January 2018 to March 2019. Urinary L-FABP and serum creatinine were measured at 2 and 6 hours, and 1, 2, 3, 7 and 28 days after taking cisplatin. Results In the first week after receiving cisplatin, 10 patients (23.8%) were diagnosed with AKI (AKI+ group). Pre-treatment (baseline) measurements did not significantly differ between the AKI+ and AKI− groups. However, urinary L-FABP concentrations rapidly increased in the AKI+ group and were significantly greater than in the AKI− group at Hour 2, Hour 6, Day 1 and Day 2. Serum creatinine also significantly differed between the AKI+ group and the AKI− group on Days 3 and 7. Conclusions Acute renal function deterioration was predicted by increased urinary L-FABP excretion within six hours after receiving CIS-CT and, in those with AKI, the increase in urinary L-FABP excretion preceded the rise in sCr by over 2 days. In contrast, no appreciable changes in urinary L-FABP levels were observed in patients with stable renal function throughout the whole observation period. So early increase in urinary L-FABP may identify patients at risk of cisplatin-induced AKI, who might benefit from treatment to prevent nephrotoxicity. Trial registration: This study was retrospectively registered.
- 1 July 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (6) , 1939-1944
Serum Brain-Derived Neurotrophic Factor and Myostatin Levels Are Associated With Skeletal Muscle Mass in Kidney Transplant Recipients
- 1 July 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (6) , 1939-1944
Serum Brain-Derived Neurotrophic Factor and Myostatin Levels Are Associated With Skeletal Muscle Mass in Kidney Transplant Recipients
- 1 January 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (1) , 84-88
Adherent Perinephric Fat Is a Surgical Risk Factor in Laparoscopic Single-Site Donor Nephrectomy: Analysis Using Mayo Adhesive Probability Score
- 1 January 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (1) , 84-88
Adherent Perinephric Fat Is a Surgical Risk Factor in Laparoscopic Single-Site Donor Nephrectomy: Analysis Using Mayo Adhesive Probability Score
- 30 July 2019
- Published by S. Karger AG in Urologia Internationalis
- Vol. 104 (1-2) , 70-74
Laparoendoscopic Single-Site Surgery for Urachal Remnants: A Single-Center Experience
Introduction: Urachal remnants are relatively rare. Generally, urachal remnants are detected in young people, and the removed specimen is small, comprising a good indication for laparoscopic surgery. Laparoendoscopic single-site surgery (LESS) for urachal remnants is considered to be safe and result in an excellent cosmetic outcome. Therefore, we report our single-center experience with LESS for urachal remnants. Methods: We retrospectively reviewed 30 patients with urachal remnants who underwent LESS from January 2011 to December 2017. The patients’ characteristics, surgical data, postoperative pain, and cosmetic assessment results were retrospectively collected and analyzed. Results: Mean total operative time was 151 min, mean pneumoperitoneal surgery time was 83 min, and mean estimated blood loss was 5.0 mL. All patients were started on an oral diet and began ambulating on postoperative day 1. Mean hospital stay was 5.5 days. LESS was completed successfully in all patients, with no conversion to conventional or open surgery. Conclusions: LESS is a viable option for the surgical treatment of urachal remnants. This technique may result in less pain than conventional techniques. Further accumulation of surgical outcomes (especially regarding safety and cosmesis) is required for LESS to become an established treatment for urachal remnants.
- 30 July 2019
- Published by S. Karger AG in Urologia Internationalis
- Vol. 104 (1-2) , 70-74
Laparoendoscopic Single-Site Surgery for Urachal Remnants: A Single-Center Experience
Introduction: Urachal remnants are relatively rare. Generally, urachal remnants are detected in young people, and the removed specimen is small, comprising a good indication for laparoscopic surgery. Laparoendoscopic single-site surgery (LESS) for urachal remnants is considered to be safe and result in an excellent cosmetic outcome. Therefore, we report our single-center experience with LESS for urachal remnants. Methods: We retrospectively reviewed 30 patients with urachal remnants who underwent LESS from January 2011 to December 2017. The patients’ characteristics, surgical data, postoperative pain, and cosmetic assessment results were retrospectively collected and analyzed. Results: Mean total operative time was 151 min, mean pneumoperitoneal surgery time was 83 min, and mean estimated blood loss was 5.0 mL. All patients were started on an oral diet and began ambulating on postoperative day 1. Mean hospital stay was 5.5 days. LESS was completed successfully in all patients, with no conversion to conventional or open surgery. Conclusions: LESS is a viable option for the surgical treatment of urachal remnants. This technique may result in less pain than conventional techniques. Further accumulation of surgical outcomes (especially regarding safety and cosmesis) is required for LESS to become an established treatment for urachal remnants.